KEY POINTS IN FERTILITY PRESERVATION TREATMENT STRATEGIES DURING COVID-19 PANDEMIC. AN UPDATE ON PHARMACOLOGICAL THERAPIES

The fertility preservation (FP) field has developed in the two decades and offers women possibility to have genetic children at some point life. Fertility is urgent by definition, performed for social reasons or medical indications, such as impending gonadotoxic therapy radical gynaecological surgery. One year after pandemic was declared, COVID-19 infection imposed several restrictions limited access health care infertile couple. Ovarian stimulation a pharmacological treatment used induce development of ovarian follicles;FP guidelines provide different options stimulation. We systematic search on procedures during using keywords: FP, stimulation, assisted reproduction techniques (ART), COVID-19. In order update strategies studied last ten years, we searched randomized clinical trials (RCTs) focused therapeutic agents current protocols, gonadotropins, gonadotropin releasing hormone (GnRH), clomiphene citrate (CC), letrozole, androgens, metformin, tamoxifen, glucocorticoids, aspirin, coenzyme Q10, sildenafil. may be influenced SARS-CoV-2 - especially men;until more evidence confirms effects fertility, patients with positive should delay FP if possible. Access conservation services decreased analysed period due reorientation resources COVID-19, without major changes protocols. terms pharmacotherapy (OS) procedures, letrozole first line therapy, superior CC OS. Similar ovulation pregnancy rate can obtained induced compared protocol. Adjuvant therapies OS but lack proven efficacy. Further studies adjuvant complementary support are needed, ensure optimal condition reproductive interventions preservation, therapies.